Pharm
Physostigmine
search
Physostigmine
See Also
Anticholinergic Toxicity
Indications
Incapacitating Agent
exposure (e.g. BZ, Agent 15)
Anticholinergic
Overdose
(e.g.
Diphenhydramine
,
Atropine
)
Pharmacokinetics
Reversibly binds
Acetylcholine
sterase (short-acting
Acetylcholinesterase Inhibitor
)
Related to
Pyridostigmine
Lasts only 30 to 60 minutes
May require frequent redosing as below
Routes
Intramuscular
Adults: 0.05 mg/kg
Child: 0.02 mg/kg
Intravenous
Dose: 0.02 mg/kg up to 1-2 mg
Available in 2 mg/2 ml vials
Dilute one 2 mg Physostigmine vial in 8 cc NS within a 10 cc syringe and infuse slowly
Infuse over 2-10 minutes or slower and may repeat every 30 minutes (as often as every 10-20 min)
Risk of
Seizure
if infused too quickly
Oral: 60 mcg/kg (bitter taste, dilute in juice)
Protocol
Example in Adults
Initial: 2-3 mg IM or 2 mg slow IV (see above)
Repeat: every 30-60 minutes prn depressed mental status
Maintenance: 2-4 mg IV slowly every 2-4 hours prn
Taper: Slowly taper over hours to 4-5 days
Precautions
Consult toxicology (esp. if more than one dose is needed)
Adverse Effects
Bradycardia
(common, related to increased vagal tone)
Atropine
0.5 to 1 mg may be given to counter significant
Bradycardia
or bronchorrhea
Bronchorrhea
Vomiting
Consider pretreatment with
Ondansetron
See
Cholinergic Toxicity
Contraindications
Cardiac conduction abnormality (Obtain EKG prior to administration)
Bradycardia
Intraventricular conduction delay
AV Nodal block
Tricyclic Overdose
Physostigmine was part of coma cocktail (mix of antidotes to counter
Overdose
) in 1980s
Physostigmine fell out of favor in general due to worse outcomes in TCA
Overdose
Uncontrolled
Asthma
or
Wheezing
Seizure Disorder
References
(2016)
CALS
Manual, 14th ed, 1:133
Orman and Hatten in Herbert (2016) EM:Rap 16(4): 6
Type your search phrase here